Global Androgen
Replacement Therapy Market, by Product Type (Testosterone Creams/Gels,
Testosterone Patches, Testosterone Injections, Testosterone Implants, and
Testosterone Tablets/Capsules/Gums), by Active Ingredient Type (Testosterone,
Methyl Testosterone, Testosterone Undecanoate, Testosterone Enanthate, and
Testosterone Cypionate), by Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, and Online Pharmacies), and
by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and
Africa), is estimated to be valued at US$ 1,965.5 million in 2021 and is
expected to exhibit a CAGR of 7.8% during the forecast period (2021-2028).
Product approval by regulatory
authorities is expected to drive growth of the global androgen replacement
therapy market during the forecast period. For instance, in October 2018,
Antares Pharma received the U.S. FDA approval for XYOSTED (testosterone
enanthate) injection. XYOSTED is the first U.S. FDA approved subcutaneous
testosterone enanthate product for once-weekly, at-home self-administration
with an easy-to-use, single dose, disposable QuickShot auto injector. XYOSTED
has been approved in three dosage strengths- 50 mg, 75 mg, and 100 mg, and is
indicated for testosterone replacement therapy in adult males for conditions
associated with a deficiency or absence of endogenous testosterone.
Key players are focused on
development and launch of new advanced androgen replacement therapies in the
market, which is expected to contribute significantly to the androgen
replacement therapy market growth. For instance, in October 2018, Perrigo
Company plc. announced the launch of an AB-rated generic version of Androgel
Topical Gel, 1.62% (20.25mg testosterone/1.25g packet, 40.5mg testosterone/2.5g
packet, and 20.25mg/1.25g actuation pump).
Global Androgen Replacement
Therapy Market - Impact of Coronavirus (COVID – 19) Pandemic
COVID-19 outbreak was first
reported on December 31, 2019 in Wuhan, China. According to the Coronavirus
(COVID-19) Weekly Epidemiological Update by the World Health Organization, over
146 million cases and 3.1 million deaths due to coronavirus (COVID-19) were
reported up till April 25th, 2021 across the globe.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/3787
The coronavirus (COVID-19)
pandemic and lockdown in various countries across the globe has impacted the
financial status of businesses in all sectors. The private healthcare sector is
one of the sectors which has been majorly affected by the pandemic. The
lockdown in various countries have created an economic burden on the private
healthcare sector. Healthcare providers are facing challenges with regards to
manpower, equipment, consumables, and other resources to ensure safety of
patients with other diseases, and declining outpatient’s visits among others.
Moreover, the pandemic has
negatively impacted the development, production, and supply of drugs, and
affected growth of the healthcare segment of various companies across the
globe. This has led to closure of industrial establishments, except
manufacturing of essential commodities and disruption in supply chain of
products. The COVID-19 pandemic has affected the economy in three main ways: 1)
by directly affecting the production and demand; 2) by creating disruptions in
distribution channels; and 3) through its financial impact on companies and
financial markets.
Supply chain and manufacturing
activities in India, China, the U.S., and others have been disrupted due to
lockdowns. Whereas, countries such as Thailand, Indonesia, Singapore, and
others are facing problems with transportation of drugs and medications. The
COVID-19 pandemic is expected to slightly disrupt the R&D activities in the
androgen replacement therapy market.
Browse 39 Market Data Tables and
22 Figures spread through 191 Pages and in-depth TOC on Global Androgen
Replacement Therapy Market, by Product Type (Testosterone Creams/Gels,
Testosterone Patches, Testosterone Injections, Testosterone Implants, and
Testosterone Tablets/Capsules/Gums), by Active Ingredient Type (Testosterone,
Methyl Testosterone, Testosterone Undecanoate, Testosterone Enanthate, and
Testosterone Cypionate), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies,
and Online Pharmacies), and by Region (North America, Latin America, Europe,
Asia Pacific, Middle East, and Africa).
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/androgen-replacement-therapy-market-3787
Several market players are
focused on acquisition of commercial rights to expand their product portfolio
and gain maximum share of market. For instance, in April 2016, Aytu BioScience,
Inc., announced the exclusive licensing of its third commercial-stage urology
product in just 11 months, with the execution of a long-term, exclusive license
agreement with an affiliate of Acerus Pharmaceuticals Corporation for the U.S.
commercial rights to Natesto (testosterone) Nasal Gel. Natesto is the first and only nasal
formulation of testosterone approved by the U.S. Food and Drug Administration
(FDA), as a replacement therapy for men diagnosed with hypogonadism.
Key Takeaways of the Androgen
Replacement Therapy Market:
The global androgen replacement
therapy market is expected to exhibit a CAGR of 7.8% over the forecast period
(2021-2028), owing to growth in potential markets, especially in Europe. While,
North America accounted for the major market share over the forecast period
(2021 -2028).
Market players are indulged in
launching of products, which is expected to drive growth of the global androgen
replacement therapy market over the forecast period. For instance, in April
2020, Xiromed LLC launched Testosterone Gel 1.62% Metered Dose Pump
(20.25mg/1.25g pump actuation), an AB-rated generic version of AndroGel 1.62%.
AndroGel 1.62% is indicated for replacement therapy in males for conditions
associated with a deficiency or absence of endogenous testosterone.
Some of the major players
operating in the global androgen replacement therapy market include AbbVie,
Inc., Bayer AG, Endo Pharmaceuticals, Plc., Eli Lilly and Company, Kyowa Kirin
International Plc., Novartis International AG, Pfizer Inc., Clarus
Therapeutics, Inc., Perrigo Company Plc, Acerus Pharmaceuticals Corporation,
Sawai pharmaceutical Co., Ltd., Reddy's Laboratories, Sun Pharmaceutical
Industries Ltd., and Simple Pharma.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/3787
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment